Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.67 |
| ▸ | HRH1 | P35367 | 3/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264638 | 0.88 | HTR2A (0.66) | HTR2AHRH1IDO1CA1CA2 | |
| SCHEMBL5353138 | 0.85 | HTR2A (0.64) | HTR2AHRH1CA1CA2KMT2A | |
| SCHEMBL1199989 | 0.85 | HTR2A (0.59) | HTR2AHRH1IDO1CA1CA2 | |
| SCHEMBL7574105 | 0.82 | HTR2A (0.61) | HTR2AHRH1CA1CA2KMT2A | |
| SCHEMBL17022715 | 0.82 | HTR2A (0.61) | HTR2AHRH1CA1CA2KMT2A | |
| Hydrochloric Acid SCHEMBL6557729 | 0.80 | HTR2A (0.58) | HTR2AHRH1CA1CA2KMT2A | |
| SCHEMBL29902960 | 0.80 | HTR2A (1.00) | HTR2AHRH1CA1CA2KMT2A | |
| SCHEMBL1402081 | 0.80 | HTR2A (1.00) | HTR2AHRH1CA1CA2KMT2A | |
| Hydrochloric Acid SCHEMBL8638272 | 0.79 | HTR2A (0.48) | HTR2AHRH1KMT2AGPR3 | |
| Hydrochloric Acid SCHEMBL3895426 | 0.78 | HTR2A (0.95) | HTR2AHRH1CA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374730-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2404608-B1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | OTSUKA PHARMA CO LTD (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-20140178464-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-1921086-B1 | ANTITUMOR AGENT | OTSUKA PHARMA CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2251014-B1 | COMBINATIONS OF AN ANTI-CANCER AGENT AND A CHOLESTANOL DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-20130101679-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | YAZAWA SHIN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120015025-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1921086-A1 | ANTITUMOR AGENT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | disclosed |
| US-20060193903-A1 | Glycoside-containing liposome | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647277-A1 | GLYCOSIDE-CONTAINING LIPOSOME | Otsuka Pharmaceutical Company, Limited (JP) | 2006-04-19 | — | — | EP | disclosed |
| EP-0179630-B1 | N6-ACENAPHTHYL ADENOSINES AND ANALOGS THEREOF | WARNER-LAMBERT COMPANY (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4847241-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1989-07-11 | — | — | US | disclosed |
| US-4663313-A | N6 -tricyclic adenosines for treating hypertension | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| US-4593019-A | Therapy for psychosis | WARNER-LAMBERT COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0179630-A2 | N6-acenaphthyl adenosines and analogs thereof | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0163458-A1 | Tetrahydronaphthalenols for the treatment of hypertension | E.R. Squibb & Sons, Inc. (US) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101679-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | ALG1, FUT5, ALG8 | HTR2A 4162/4885HRH1 4859/4885IDO1 2121/4885 |
| US-20120015025-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | ALG1, FUT5, ALG8 | HTR2A 4162/4885HRH1 4859/4885IDO1 2121/4885 |
| US-20150374730-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | ALG1, FUT5, ALG8 | HTR2A 4162/4885HRH1 4859/4885IDO1 2121/4885 |
| US-20060193903-A1 | Glycoside-containing liposome | FUT5, FUT6, ALG1 | HTR2A 3019/4885HRH1 4272/4885IDO1 2564/4885 |
| US-20140178464-A1 | CHOLESTANOL DERIVATIVE FOR COMBINED USE | ALG1, FUT5, ALG8 | HTR2A 4162/4885HRH1 4859/4885IDO1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.